Daniel J. Hicklin

Daniel J. Hicklin's AcademicInfluence.com Rankings

Daniel J. Hicklin

Biology

#9226

World Rank

#12407

Historical Rank

biology Degrees

Download Badge

Biology

Daniel J. Hicklin's Degrees

PhD Biomedical Sciences University of California, San Francisco
Bachelors Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Daniel J. Hicklin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Daniel J. Hicklin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche (2005) (2975)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. (2005) (2723)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (2006) (2509)
Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. (2000) (2433)
Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth (2001) (1988)
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions (2001) (1669)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. (2005) (1584)
VEGF-targeted therapy: mechanisms of anti-tumour activity (2008) (1579)
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. (2004) (1263)
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. (2000) (1220)
Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors (2004) (1136)
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 (2002) (1099)
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration (2001) (1032)
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. (2008) (1030)
Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis (2004) (784)
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 (2003) (782)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (2000) (774)
Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells (2001) (717)
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. (1999) (715)
Vascular Trauma Induces Rapid but Transient Mobilization of VEGFR2+AC133+ Endothelial Precursor Cells (2001) (706)
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment (2002) (678)
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes (2006) (662)
Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors (2006) (595)
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. (2005) (595)
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. (2001) (559)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity (2000) (557)
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. (2002) (556)
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. (2013) (534)
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. (1999) (499)
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy (2002) (466)
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. (2000) (456)
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. (2000) (441)
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. (2007) (398)
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. (1999) (382)
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. (2003) (374)
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. (2002) (369)
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. (2005) (360)
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells (2005) (340)
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. (2002) (333)
Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. (2004) (319)
Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. (2001) (313)
Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. (2001) (309)
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias (2001) (285)
Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis (2003) (281)
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy (1998) (281)
Effect of platelet-derived growth factor on tibial osteotomies in rabbits. (1994) (281)
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. (1999) (264)
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. (2006) (261)
Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. (2002) (253)
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors (2001) (249)
Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. (2005) (248)
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy (2008) (243)
Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. (2002) (242)
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. (2007) (238)
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. (2000) (238)
Granulocyte colony‐stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils (2005) (232)
Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. (2005) (231)
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology (2009) (231)
Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9–mediated progenitor cell mobilization (2005) (227)
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. (2004) (225)
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose (2008) (214)
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. (2004) (212)
A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. (2006) (212)
Vascular endothelial growth factor receptor‐1 promotes migration and invasion in pancreatic carcinoma cell lines (2005) (208)
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. (1998) (207)
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases (2000) (202)
A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. (2002) (198)
A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism (2007) (194)
A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* (2005) (193)
Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. (1999) (185)
The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma (2006) (184)
HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. (1998) (177)
Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice (2004) (177)
Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies (2004) (167)
Epidermal growth factor receptor blockade by antibody IMC‐C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice (2000) (167)
Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis (2002) (165)
Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy (2006) (159)
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. (2006) (157)
Cooperative and redundant roles of VEGFR‐2 and VEGFR‐3 signaling in adult lymphangiogenesis (2007) (152)
Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts (2006) (151)
Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma (2002) (151)
Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. (1998) (150)
Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer (2006) (148)
Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice (2002) (147)
Antiangiogenic therapy—evolving view based on clinical trial results (2012) (142)
A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens (2004) (134)
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. (2004) (133)
HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. (2008) (132)
Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. (2007) (131)
Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases (2006) (131)
Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. (2006) (130)
Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. (2000) (130)
Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. (2000) (129)
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. (2000) (127)
Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells (2003) (123)
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. (2002) (120)
Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. (2002) (119)
Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme (2002) (119)
Different Requirements for Signal Transducer and Activator of Transcription 1α and Interferon Regulatory Factor 1 in the Regulation of Low Molecular Mass Polypeptide 2 and Transporter Associated with Antigen Processing 1 Gene Expression* (1998) (118)
Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target (2005) (118)
Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab Augments Radiation Effects in Glioblastoma Multiforme in Vitro and in Vivo (2005) (117)
Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. (1998) (111)
Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. (2002) (111)
Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. (2002) (109)
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor (2007) (109)
Vascular endothelial growth factor receptor 2 blockade disrupts postnatal lung development. (2005) (106)
Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. (2000) (102)
Vascular endothelial growth factor receptor 2 (VEGFR-2) functions to promote uterine decidual angiogenesis during early pregnancy in the mouse. (2009) (101)
Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice (2004) (101)
Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. (2002) (96)
Insulin-like growth factor-I receptor signaling blockade combined with radiation. (2007) (95)
Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. (2005) (94)
KDR/Flk‐1 is a major regulator of vascular endothelial growth factor–induced tumor development and angiogenesis in murine hepatocellular carcinoma cells (1999) (93)
Tyrosine kinase receptor RON in human pancreatic cancer (2007) (93)
&bgr;3-Integrin Regulates Vascular Endothelial Growth Factor-A–Dependent Permeability (2004) (88)
Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. (2006) (83)
Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy (2007) (81)
Monoclonal antibody therapeutics and apoptosis (2003) (80)
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. (2005) (80)
Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. (2001) (77)
Monoclonal antibody strategies to block angiogenesis. (2001) (74)
Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. (2005) (68)
Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development (2004) (64)
Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro (2004) (64)
Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. (2009) (61)
Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non–small cell lung cancers (2007) (61)
Effect of molecular therapeutics on liver regeneration in a murine model. (2008) (60)
Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. (1999) (56)
Neonatal hypoxic preconditioning involves vascular endothelial growth factor (2007) (55)
Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. (2004) (54)
Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts (2004) (54)
The vascular endothelial growth factor receptor KDR/Flk‐1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model (2001) (53)
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. (2005) (52)
Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab (2007) (49)
Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. (2005) (49)
Targeting the Vascular Endothelial Growth Factor Pathway in the Treatment of Human Malignancy (2007) (47)
Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy (2007) (45)
Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF. (2005) (44)
Vascular endothelial growth factor receptor 3 in hypoxia‐induced vascular development (2004) (44)
Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. (1996) (44)
Simultaneous blockade of VEGFR‐1 and VEGFR‐2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation (2007) (42)
Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-CΔNΔC- and VEGF-A-induced angiogenesis in vitro (2003) (42)
IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. (2006) (41)
Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies. (2007) (38)
Anti‐vascular endothelial growth factor receptor‐2 (Flk‐1/KDR) antibody suppresses contact hypersensitivity (2004) (37)
Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer (2006) (37)
Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. (2005) (35)
Inhibition of Both the Autocrine and the Paracrine Growth of Human Leukemia with a Fully Human Antibody Directed Against Vascular Endothelial Growth Factor Receptor 2 (2004) (35)
VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. (2000) (34)
Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts. (2003) (33)
β2-Microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance (1997) (32)
Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors. (2007) (31)
Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. (2004) (27)
FLT 3 ligand causes autocrine signaling in acute myeloid leukemia cells (2003) (25)
Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. (1996) (24)
Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies. (2008) (24)
VEGF receptor 2 blockade leads to renal cyst formation in mice. (2006) (24)
Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system. (2007) (24)
VEGFR-1 and -2 Regulate Inflammation, Myocardial Angiogenesis, and Arteriosclerosis in Chronically Rejecting Cardiac Allografts (2007) (23)
Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed. (2004) (19)
Identification and characterization of a fully human antibody directed against epidermal growth factor receptor for cancer therapy (2004) (17)
SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics (2010) (17)
Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. (2005) (15)
Function of the Vascular Endothelial Growth Factor Receptors Flt-1 and Flk-1/KDR in the Alloimmune Response In Vivo (2005) (15)
Human Tumor Xenograft Efficacy Models (2011) (14)
Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro. (2003) (14)
Antitumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC-11F8) in human tumor xenograft models (2004) (13)
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors. (2016) (13)
Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. (2008) (13)
Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. (2008) (13)
cDNA cloning, chromosomal mapping, and expression analysis of human VE-Cadherin-2 (2000) (11)
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models. (2009) (11)
Promoting angiogenesis to a fault (2007) (10)
Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy. (2003) (9)
Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression (2022) (8)
Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis. (2006) (8)
HIF-1 (cid:1) regulates epithelial inﬂammation by cell autonomous NF (cid:2) B activation and paracrine stromal remodeling (2008) (7)
314 Anti-tumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC-11F8) in human colon carcinoma xenograft models with enhanced activity in combination with CPT-11 (2004) (6)
Characterization of rabbit antisera elicited with human LMP2- and LMP7-specific peptides and recombinant proteins. (1997) (6)
Corrigendum: Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes (2006) (6)
Effect of molecular therapeutics on liver regeneration in a murine model (2007) (5)
Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody. (2021) (5)
IMC-A12 enhances the efficacy of cetuximab + gemcitabine therapy in human pancreatic carcinoma xenografts. (2007) (5)
VEGF receptor expression on reactive breast cancer stroma: paving the way for tumor invasion (2005) (4)
SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors (2011) (4)
Kinetics of vascular normalisation by VEGFR2 blockade governs brain tumour response to radiation: role of angiopoietin-1 and matrix metalloproteinases (2005) (4)
Induction of Endothelial Cell Apoptosis Growth of Human Soft Tissue Sarcoma Xenografts by Continuous Low-Dose Doxorubicin Inhibits Angiogenesis and Combined Anti-Fetal Liver Kinase 1 Monoclonal Antibody and Updated (2002) (3)
207 POSTER Combined antibody mediated inhibition of IFG-IR, EGFR, and VEGFR2 for more consistent and greater antitumor effects (2006) (3)
High density of small vessels expressing the tyrosine kinase receptor KDRin primary invasive breast carcinoma correlates with axillary lymph node metastases (2004) (3)
Epidermal Growth Factor Receptor Blockade with C 225 Plus Gemcitabine Results in Regression of Human Pancreatic Carcinoma Growing Orthotopically in Nude Mice by Antiangiogenic Mechanisms 1 (2000) (2)
Kaplan et al. reply (2009) (2)
718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models (2021) (2)
The Anti-FLT3 Monoclonal Antibody EB10 Is Cytotoxic to FLT3 Inhibitor Resistant Cells In Vivo. (2005) (2)
Kinase ( RON ) , a c-MET Family Member to the Macrophage-Stimulating Protein Receptor Tyrosine Therapeutic Implications of a Human Neutralizing Antibody (2006) (2)
A fully human monoclonal antibody against VEGFR-1 inhibits growth of human breast cancers (2004) (2)
Clinical development of antibody-based receptor tyrosine kinase inhibitors for cancer therapy (2001) (2)
In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2. (2009) (2)
Expression and function of vascular endothelial growth factor receptor–1 in human colon cancer cells (2004) (1)
EB10, an Anti-FLT3 Monoclonal Antibody, Selectively Targets ALL Cell Lines and Primary ALL Blasts without Interfering with Normal Hematopoiesis. (2004) (1)
Vascular Endothelial Growth Factor Receptor Antibodies for Anti-Angiogenic Therapy (2008) (1)
162 In vivo effects of a monoclonal antibody to the murine VEGFR-3 that antagonizes the binding of VEGF-C and receptor signaling (2004) (1)
Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody Reduces Tumorigenicity and Metastasis in Orthotopic Prostate Cancer Xenografts via Induction of Endothelial Cell Apoptosis and Reduction of Endothelial Cell Matrix Metalloproteinase Type 9 Production 1 (2002) (1)
Hormone Ablation , and Chemotherapy Vascular Endothelial Growth Factor Receptor-2 Blockade , Tumor Oxygenation in Hormone-Dependent Tumors During Updated (2000) (1)
Abstract 1723: WTX-124 is an IL-2 pro-drug conditionally activated in tumors and able to induce complete regressions in mouse tumor models (2021) (1)
Role of vascular endothelial growth factor (VEGF) in experimental obliterative bronchiolitis (OB) (2005) (1)
217 POSTER Circulating levels of ligand as a potential biomarker for optimal dosing of targeted antibody drugs to the epidermal growth factor receptor (2006) (1)
70 Therapeutic human monoclonal antibody targeting VEGFR-1 suppresses growth of human breast cancers (2004) (1)
Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates (2021) (1)
525: Role of Vascular Endothelial Growth Factor Receptors 1 and 2 in Experimental Obliterative Airway Disease (2009) (1)
Supression of FLT3-Expressing Leukemia by a Monoclonal Antibody-Auristatin Conjugate. (2004) (1)
Tumor bed irradiation enhances sensitivity of A431 tumor xenografts to C225 anti-EGFR antibody (2008) (1)
CCR 20th Anniversary Commentary: In Search of Cetuximab's First Indication—Combination Therapy with Irinotecan in Colorectal Cancer (2015) (1)
723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models (2021) (1)
MONOTHERAPY WITH EVEROLIMUS OR FTY720 AMELIORATES CHRONIC ALLOGRAFT NEPHROPATHY (CAN) AT LATE STAGES, WHILE THE COMBINATION WITH CYCLOSPORINE DOES NOT TREAT CAN (2006) (1)
AVascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-BasedMechanism (2007) (1)
Impact of circulating endothelial progenitor cells on the growth of viable tumor rim after treatment with a vascular disrupting agent. (2006) (1)
SCH 727965, a novel cyclin-dependent kinase inhibitor, has potent anti-tumor acitivity in a wide-spectrum of human tumor xenograft models (2008) (1)
Increased ligand as a biomarker to guide optimal dosing of targeted antibody drugs to receptor tyrosine kinases (2005) (1)
Antiangiogenic drugs as broadly effective chemosensitizing agents (2006) (1)
β: molecular characterization and implications for immune surveillance2: molecular characterization and implications for immune surveillance-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance (1997) (1)
363 Targeting of PDGF receptors; combination effects in various solid tumors and identification of a PDGF dependent brain tumor subset (2004) (0)
Combined anti-vascular effects of VEGFR-2 blockade and inhibition of nitric oxide (2005) (0)
SIGNIFICANCE OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS RECEPTORS IN LIVER ISCHEMIA REPERFUSION INJURY (2004) (0)
human lymphoma xenografts in vivo Targeting autocrine and paracrine VEGF receptor pathways inhibits (2013) (0)
Activity of small molecule inhibitors of the epidermal growth factor receptor (EGFR) kinase, on EGFR kinase domain mutants (2005) (0)
Suppression of leukemia growth in vivo by a novel anti-FLT3 antibody-auristatin conjugate (2005) (0)
Evaluating The Role Of b3‐Integrins In Angiogenesis (2006) (0)
Abstract 2785: Discovery of a novel HDM2 inhibitor with potent in vivo anti-tumor activity (2012) (0)
Receptor antibodies 1 vascular endothelial growth factor (2005) (0)
A randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for Her2 negative breast cancers. (2009) (0)
VEGF DRIVEN INTERPLAY OF INFLAMMATION AND PRIMITIVE CAPILLARY ANGIOGENESIS IN CHRONICALLY REJECTING (2006) (0)
Antagonistic antibodies against ve-cadherin without negative effects on vascular permeability (2001) (0)
536 POSTER Comparison of the tumor growth inhibitory effects of tumor cell and non-tumor cell EGFR targeted antibodies in cancer models (2008) (0)
Abstract 2727: The discovery and characterization of PTZ-201, a fully-human, high affinity, antagonistic anti-TIGIT monoclonal antibody (2018) (0)
Signaling and Inhibits Human Tumor Growth Growth Factor I Receptor Blocks Ligand-Dependent A Fully Human Monoclonal Antibody to the Insulin-Like Updated (2003) (0)
1096 mWTX-330, an IL-12 INDUKINE molecule, selectively activates tumor infiltrating lymphocytes and reprograms the tumor microenvironment in murine syngeneic tumor models (2022) (0)
FLT3 Immunotherapy Can Eliminate Engraftment of ALL Cells in NOD/SCID Mice. (2005) (0)
Abstract 1648: SCH 1473759, a novel aurora inhibitor, demonstrates enhanced antitumor activity in combination with taxanes and KSP inhibitors (2010) (0)
Advances in Brief Vascular Endothelial Growth Factor Receptor-2-blocking Antibody Potentiates Radiation-induced Long-Term Control of Human Tumor Xenografts 1 (2000) (0)
angiogenesis without side effects on endothelial permeability cadherin inhibits tumor - A monoclonal antibody to vascular endothelial (2013) (0)
Molecular Cancer apeutics linical Development 2047069 , a Novel Oral Kinesin Spindle Protein Inhibitor , ws Single-Agent Antitumor Activity and Enhances the Ther cacy of Chemotherapeutics (2010) (0)
Antibody-Mediated Drug Delivery in Cancer Therapy (2004) (0)
Development of Antiangiogenic Monoclonal Antibodies for Cancer Therapy (2007) (0)
Abstract 1716: WTX-330, a conditionally activated IL-12 INDUKINE, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models (2021) (0)
SIGNIFICANCE AND THERAPEUTIC POTENTIAL OF TARGETING ANGIOGENESIS IN ALLOIMMUNE RESPONSE (2004) (0)
715 WTX-330 is an IL-12 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models (2021) (0)
Vascular Endothelial Growth Factor Levels and Induction of Permeability in Malignant Pleural Effusions 1 (1999) (0)
Blockade of IGF-IR function reduces COX-2 expression in human pancreatic cancer cells (2004) (0)
308 Inhibition of FLT3-expressing leukemia cells by a monoclonal antibody-auristatin conjugate (2004) (0)
EB10, an Anti-FLT3 Monoclonal Antibody, Prolongs Survival and Reduces NOD/SCID Engraftment of AML Cell Lines and Primary Blasts. (2004) (0)
Metronomic anti-angiogenic combination therapy (2001) (0)
A ceramide rheostat balances angiogenesis and anti-angiogenesis (2008) (0)
Inhibition of leukemia growth by a recombinant gelonin conjugate of anti-FLT3 monoclonal antibody (2007) (0)
‘Angiogenesis’ abstracts from the Second China International Symposium on Angiogenesis and Hematopoiesis (2004) (0)
Abstract 2055: WTX-330 is a conditionally activated IL-12 prodrug that fundamentally reprograms tumor infiltrating CD8+ T cells and drives tumor regression (2022) (0)
Comparison of combination anti-EGFR and anti-VEGFR2 therapy to MTD standard chemotherapeutic regimens (2007) (0)
Functional expression of the anti-EGF receptor monoclonal antibody cetuximab in transgenic corn (2003) (0)
mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity. (2023) (0)
2613 : Combined Efficacy of IGF-I Signaling Blockade and Radiation in NSCLC Models (2006) (0)
Abstract 1829: Generation of IL-21 INDUKINETM molecules for the treatment of cancer (2023) (0)
Abstract 599: TMPRSS2-ERG gene fusion sensitizes VCaP human prostate tumors to the fully human anti-IGF-IR monoclonal antibody SCH 717454 (2011) (0)
Vascular Endothelial Growth Factor Family and Its Receptors (2008) (0)
132: Interplay between inflammation and angiogenesis in cardiac allografts – therapeutic applications for VEGFR-1 and -2 inhibition (2006) (0)
Abstract 4533: In vivo activation of the p53 pathway leading to tumor regression by a novel and potent HDM2 antagonist SCH 1450206 (2010) (0)
Abstract 4534: A novel and potent small molecule antagonist of HDM2, SCH 1450206, activates the p53 pathway with mechanism-based activity (2010) (0)
345: Blocking VEGF Receptors 1 and 2 Prevents Inflammatory Response and Experimental Obliterative Airway Disease (2010) (0)
Potent anti-tumor activity of IGF-I receptor antagonist antibody IMC-A12 alone and in combination with CPT-11. (2004) (0)
HLA class I antigen downregulation in malignant melanoma (2002) (0)
Abstract 1536: Characterization of tumor cell lines selected for resistance to the HDM2 antagonist Nutlin-3a (2010) (0)
Advances in Brief Inhibition of Vascular Endothelial Growth Factor-induced Receptor Activation with Anti-Kinase Insert Domain-containing Receptor Single-Chain Antibodies from a Phage Display Library (2006) (0)
Burn Trauma Induces Mobilization of Endothelial Precursor Cells into the Peripheral Circulation: 54. (2000) (0)
Abstract 2054: WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives anti-tumor immunity by activating tumor infiltrating CD8+ T cells (2022) (0)
Loss of LMP and TAP expression in human melanoma cells (1996) (0)
cadherin antagonist antibodies sees no adverse effects on vascular permeability. (2001) (0)
Abstract 3197: Differential senescent and apoptotic responses to HDM2 antagonism in p53 wild-type human solid cancer cells (2010) (0)
292 A preclinical pharmacokinetic/pharmacodynamic study for anti-PDGF receptor alpha antibody 3G3 in a human glioblastoma xenograft model (2004) (0)
Abstract 1817: WTX-613, (JZP898) a selectively activated IFNα INDUKINE™ molecule, reprograms the tumor microenvironment and generates robust anti-tumor immunity as a monotherapy and in combination with checkpoint inhibitors (2023) (0)
335: Vascular endothelial growth factor (VEGF) has a dual role in experimental obliterative bronchiolitis (OB) (2006) (0)
307 Therapeutic implications of an antibody to the human macrophage-stimulating protein receptor tyrosine kinase (RON) (2004) (0)
285 Degradation of the epidermal growth factor receptor occurs upon cetuximab treatment (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Daniel J. Hicklin?

Daniel J. Hicklin is affiliated with the following schools:

Daniel J. Hicklin's Academic­Influence.com Rankings